{
    "clinical_study": {
        "@rank": "35262", 
        "acronym": "MOA", 
        "arm_group": [
            {
                "arm_group_label": "Intra-tumoural cohort", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Intra-venous cohort", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the pattern of viral delivery and viral spread of\n      ColoAd1 within colorectal tumour tissue when administered either by intra-tumoural injection\n      or by intravenous infusion."
        }, 
        "brief_title": "Mechanism of Action Trial of ColoAd1", 
        "condition": "Resectable Colon Cancer", 
        "condition_browse": {
            "mesh_term": "Colonic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able and willing to provide written informed consent and to comply with the study\n             protocol\n\n          -  Age \u2265 18 years\n\n          -  Patients with histologically confirmed resectable colon cancer, scheduled for\n             resection of primary tumour and draining lymph nodes\n\n          -  Diagnostic colonoscopy performed at the study centre (Cohorts A and B) or a referral\n             centre (Cohort B only) and a report from this colonoscopy available for the study\n\n          -  Tumour size of 3 cm or more in diameter as estimated during diagnostic colonoscopy\n\n          -  At least 2 weeks since the last dose of any intravenous systemic chemotherapy at time\n             of first administration of ColoAd1\n\n          -  Recovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for\n             their malignancies.\n\n          -  Able to undergo surgery with general anaesthesia\n\n          -  Surgery planned and feasible within 15 days of coloAd1 administration (following IT\n             administration or following first dose of IV administration)\n\n          -  ECOG Performance Status Score of 0 or 1\n\n          -  Adequate renal function:\n\n               -  Creatinine \u2264 1.5 mg/dL or calculated creatinine clearance using the\n                  Cockcroft-Gault formula \u2265 60 mL/min, or measured creatinine clearance \u226560\n                  mL/min,\n\n               -  Absence of clinically significant haematuria on urinalysis: dipstick < 2+\n\n               -  Absence of clinically significant proteinuria on urinalysis: dipstick < 2+.\n\n          -  Adequate hepatic function:\n\n               -  serum bilirubin <1.5 x ULN\n\n               -  AST and ALT \u2264 3 x ULN\n\n          -  Adequate bone marrow function:\n\n               -  ANC \u2265  1.5 x 109/L,\n\n               -  platelets \u2265 100 x 109/L,\n\n               -  haemoglobin \u2265 90 g/L\n\n          -  Adequate coagulation tests: INR \u2264 1.5 x ULN;\n\n          -  For females of childbearing potential (defined as <2 years after last menstruation or\n             not surgically sterile), a negative pregnancy test must be documented prior to\n             enrolment;\n\n          -  For women who are not postmenopausal (24 months of amenorrhea) or surgically sterile\n             (absence of ovaries and/or uterus):  agreement to use two adequate methods of\n             contraception, including at least one method with a failure rate of  < 1% per year\n             (e.g., hormonal implants, combined oral contraceptives, vasectomized partner), during\n             the treatment period and for at least 3 months after the last dose of study drug;\n\n          -  For men: agreement to use a barrier method of contraception during the treatment\n             period and for at least 6 months after the last dose of study drug\n\n        Exclusion Criteria:\n\n          -  Rectal tumours\n\n          -  An obstructive tumour\n\n          -  Any condition necessitating colectomy in less than 8 days\n\n          -  Pregnant or lactating (nursing) women\n\n          -  Known and/or a history or evidence of significant immunodeficiency due to underlying\n             illness (e.g. HIV/AIDS) and/or medication (e.g. systemic corticosteroids at doses\n             higher than dexamethasone 10 mg or equivalent, or other immunosuppressive medications\n             including cyclosporine, azathioprine, interferons, within the past 4 weeks)\n\n          -  Splenectomy\n\n          -  Prior allogeneic or autologous bone marrow or organ transplantation\n\n          -  Active infections requiring antibiotics, physician monitoring, or recurrent fevers\n             >38.0 degrees centigrade associated with a clinical diagnosis of active infection\n\n          -  Active viral disease, positive serology for HIV, hepatitis B or hepatitis C\n\n          -  Use of the following anti-viral agents:\n\n               -  ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1\n\n               -  or PEG-IFN (within 14 days prior to day 1)\n\n          -  Administration of an investigational drug within 28 days prior to first dose of\n             ColoAd1\n\n          -  Major surgery within 4 weeks or radiotherapy within 3 weeks prior to first dose of\n             ColoAd1\n\n          -  Another primary malignancy within the past 3 years (except for non-melanoma skin\n             cancer or cervical cancer in situ)\n\n          -  Known CNS metastasis\n\n          -  Inflammatory diseases of the bowel\n\n          -  Any condition or illness that, in the opinion of the Investigator or the medical\n             monitor, would compromise patient safety or interfere with the evaluation of the\n             safety of the drug\n\n          -  Known allergy to treatment medication or its excipients\n\n          -  Any other medical or psychological condition that would preclude participation in the\n             study or compromise ability to give informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02053220", 
            "org_study_id": "ColoAd1-1002"
        }, 
        "intervention": {
            "arm_group_label": [
                "Intra-tumoural cohort", 
                "Intra-venous cohort"
            ], 
            "description": "Oncolytic virus", 
            "intervention_name": "Colo-Ad1", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 31, 2014", 
        "location": [
            {
                "contact": {
                    "email": "ramonsalazar@iconcologia.net", 
                    "last_name": "Ramon Salazar, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "ICO L'Hospitalet Llobregat"
                }, 
                "investigator": {
                    "last_name": "Ramon Salazar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "emiliano.calvo@start.stoh.com", 
                    "last_name": "Emiliano Calvo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Madrid Sanchinarro CIOCC"
                }, 
                "investigator": {
                    "last_name": "Emiliano Calvo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rgcarbonero@gmail.com", 
                    "last_name": "Rocio G Carbonero, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seville", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Virgen del Roc\u00edo"
                }, 
                "investigator": {
                    "last_name": "Rocio G Carbonero, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Colon Cancer Who Are Candidates for Resection of Primary Tumour", 
        "overall_contact": {
            "email": "christine.blanc@psioxus.com", 
            "last_name": "Christine Wilkinson-Blanc, MD"
        }, 
        "overall_contact_backup": {
            "email": "john.beadle@psioxus.com", 
            "last_name": "John Beadle, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the pattern of viral delivery and viral spread of ColoAd1 within colorectal tumour tissue when administered either by intra-tumoural injection or by intravenous infusion. Viral delivery and spread will be measured by immunohistochemical staining for ColoAd1 in tumour sections taken from patients. Presence of virus will also be detected by qPCR analysis of tumour tissue.", 
            "measure": "Composite measure of viral delivery and spread", 
            "safety_issue": "No", 
            "time_frame": "Up to day-15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02053220"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "PsiOxus Therapeutics Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PsiOxus Therapeutics Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}